Market research
VYGR Voyager Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 209M
- P/E ratio
- Not available
- Analyst target
- 14.8889
- Dividend yield
- Not available
- Beta
- 1.31
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92915B1061
- Market cap
- 209M
- P/E ratio
- Not available
- Analyst target
- 14.8889
- Dividend yield
- Not available
- Beta
- 1.31
About
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VYGR discussion.
5 years, 4 months ago
Voyager Therapeutics, Inc is currently in a long term downtrend where the price is trading 44.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Voyager Therapeutics, Inc's total revenue sank by 80.0% to $7M since the same quarter in the previous year.
Its net income has dropped by 26.7% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 4.5% to $-26M since the same quarter in the previous year.
Based on the above factors, Voyager Therapeutics, Inc gets an overall score of 2/5.